Clinical Trials Information
Nektar Therapeutics is focused on the clinical development of our investigational medicines to evaluate them for both safety and efficacy, especially for medical conditions where there are no effective approved medicines.
Before a new therapy can be made available to the general public, rigorous tests involving multiple studies on human volunteers are required. These studies, referred to as clinical trials, are carefully conducted and are regulated by the Food and Drug Administration (FDA) in the United States and by similar regulatory agencies worldwide. Participation in clinical trials allows patients to potentially gain access to the latest investigational treatments at little to no cost, while also playing a vital role in advancing medicine.
Nektar Therapeutics is recruiting patients in the U.S. and other countries for the following active clinical trials. Please follow the links below for more information on the enrollment criteria for each study and site location:
A phase 3, randomized, open-label study of bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients with previously untreated, unresectable or metastatic melanoma
A phase 3, randomized study of bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy or standard of care for the neoadjuvant and adjuvant treatment of patients with cisplatin-ineligible muscle-invasive bladder cancer
A phase 2 study of the triplet combination of bempegaldesleukin with nivolumab (NIVO) and cabozantinib (CABO) versus NIVO plus CABO for the treatment of renal cell carcinoma that is advanced or has spread
A Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, PK, preliminary antitumor activity and effect of biomarkers of XL092 in combination with nivolumab + bempegaldesleukin in subjects with advanced solid tumors
A phase 1, open-label, multi-center, dose escalation and dose expansion study of NKTR-255 as a single agent in relapsed or refractory Hematological Malignancies and in combination with daratumumab as a salvage regimen for multiple Myeloma
Further information and background on clinical trials may be found on www.clinicaltrials.gov, a service of the U.S. National Institutes of Health (NIH).